Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762910 | 0.91 | ALDH1A1 (0.54) | L3MBTL3L3MBTL1HRH3ALDH1A1TP53 | |
| SCHEMBL3770293 | 0.88 | HRH3 (0.51) | L3MBTL3L3MBTL1HRH3LRRK2ALDH1A1 | |
| SCHEMBL3767654 | 0.87 | HPGD (0.57) | L3MBTL3L3MBTL1HRH3LRRK2ALDH1A1 | |
| SCHEMBL3765235 | 0.86 | HRH3 (0.51) | L3MBTL3L3MBTL1HRH3LRRK2ALDH1A1 | |
| SCHEMBL3766156 | 0.84 | USP2 (0.62) | L3MBTL3L3MBTL1HRH3ALDH1A1USP2 | |
| SCHEMBL3773896 | 0.83 | KDM2B (0.54) | L3MBTL3L3MBTL1ALDH1A1HPGDUSP2 | |
| SCHEMBL3770028 | 0.82 | HPGD (0.50) | L3MBTL3L3MBTL1HRH3ALDH1A1HPGD | |
| SCHEMBL3765288 | 0.81 | HRH3 (0.53) | L3MBTL3L3MBTL1HRH3ALDH1A1SLC6A4 | |
| SCHEMBL3768037 | 0.81 | HRH3 (0.55) | L3MBTL3L3MBTL1HRH3LRRK2ALDH1A1 | |
| SCHEMBL3761199 | 0.81 | ALDH1A1 (0.64) | L3MBTL1ALDH1A1TP53HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | L3MBTL3 1357/4885L3MBTL1 1468/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.